SCHEMBL1353071

SCHEMBL1353071

NNC(=O)c1ccc(NS(=O)(=O)C(F)(F)F)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
PPARA Q07869 5/20 0.56
PPARG P37231 1/20 0.56
CA2 P00918 5/20 0.56
PTPN11 Q06124 1/20 0.56
PTPN1 P18031 1/20 0.53
CA1 P00915 3/20 0.50
CA9 Q16790 1/20 0.50
EPHX2 P34913 1/20 0.49
MPO P05164 1/20 0.47
CYP3A4 P08684 1/20 0.47
KDM5A P29375 1/20 0.47
BLM P54132 1/20 0.47
GFER P55789 1/20 0.47
PMP22 Q01453 1/20 0.47
HIF1A Q16665 1/20 0.47
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.46
OGG1 O15527 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3378865 0.83 SMN1; SMN2 (0.60) MAPK1SMN1; SMN2PPARAPPARGCA2
SCHEMBL691076 0.81 GAA (0.60) MAPK1SMN1; SMN2CA2CA1EPHX2
SCHEMBL7279576 0.81 MAPK1 (0.62) MAPK1SMN1; SMN2PPARAPPARGCA2
SCHEMBL28693361 0.81 KDM4E (0.55) SMN1; SMN2PPARAPPARGCA2CA1
SCHEMBL4724618 0.79 SMN1; SMN2 (0.70) MAPK1SMN1; SMN2PPARAPPARGCA2
SCHEMBL7433625 0.79 MAPK1 (0.60) MAPK1SMN1; SMN2PPARAPPARGCA2
SCHEMBL13869090 0.79 SMN1; SMN2 (0.59) MAPK1SMN1; SMN2PPARAPPARGCA2
SCHEMBL19820394 0.79 MAPK1 (0.55) MAPK1SMN1; SMN2PPARAPPARGCA2
SCHEMBL2577714 0.77 HPGD (0.58) SMN1; SMN2CA2CA1CA9EPHX2
SCHEMBL7526116 0.77 HPGD (0.61) MAPK1SMN1; SMN2PPARAPPARGCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120136003-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-31 US disclosed
US-20110288103-A1 COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136003-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES CFTR, PKD1, PKD2 MAPK1 2718/4885SMN1; SMN2 3981/4885PPARA 1464/4885
US-20110288103-A1 COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES ORAI1, ATP2A3, ANO1 MAPK1 2523/4885SMN1; SMN2 697/4885PPARA 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.